Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 16,542 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Connective Tissue Disease Clear all

Conditions: Sarcoma, Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Bone Tumor, Bone Sarcoma
Interventions: Ascorbate, Gemcitabine; Drug
Lead sponsor: Mohammed Milhem, MBBS; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
Interventions: ULTRAFORMER MPT PLUS, Ulthera System; Device
Lead sponsor: CLASSYS Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Charlotte, North Carolina • Wilmington, North Carolina + 2 more

Conditions: TNBC - Triple-Negative Breast Cancer, Breast Cancer
Interventions: Pembrolizumab, Radiotherapy, Axatilimab; Drug · Radiation
Lead sponsor: Stephen Shiao; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis, Rheumatoid Arthritis, Arthritis, Avascular Necrosis, Acute Fracture
Interventions: Acetabular cup; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: Not listed
Enrollment: 1,593 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 1
States / cities: Warsaw, Indiana

Conditions: Epidermolysis Bullosa (EB)
Interventions: SD-101 Dermal Cream (6%), Vehicle (SD-101 0%); Drug
Lead sponsor: Paradigm Therapeutics; Industry
Eligibility: 28 Days to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Rancho Santa Margarita, California • Redwood City, California • Philadelphia, Pennsylvania + 1 more

Conditions: Lupus Erythematosus, Systemic
Interventions: Placebo, MEDI-570 0.03 MG, MEDI-570 0.1 MG, MEDI-570 0.3 MG, MEDI-570 1 MG; Other · Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 9
States / cities: Long Beach, California • San Leandro, California • Fort Lauderdale, Florida + 6 more

Conditions: Postmenopausal Bone Loss, Breast Cancer
Interventions: Not listed
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer
Interventions: Standard Dose Dense Doxorubucin and Cyclophosphamide, Standard Doxorubucin and Cyclophosphamide, Standard Docetaxel, Carboplatin, and Herceptin, Standard Docetaxel, Doxorubucin and Cyclophosphamide, Standard Docetaxel and Cyclophosphamide; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Female only
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metastatic Breast Cancer
Interventions: Palliative Radiation and Pembrolizumab; Combination Product
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Raynaud's Disease, Raynaud's Disease Secondary to Scleroderma, Raynaud's Disease Secondary to Autoimmune Disease
Interventions: MQX-503; Drug
Lead sponsor: MediQuest Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Timeline: 2006
U.S. locations: 1
States / cities: Renton, Washington

Conditions: Anakinra, Kineret, Atopic Dermatitis, Eczema, Allergic Disease
Interventions: Anakinra; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years to 30 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Eczema
Interventions: Sunflower oil, Control group, Aquaphor ointment, Cetaphil cream; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 1 Minute to 6 Months
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Cancer, Breast Cancer
Interventions: Resistance Training with Cardio, Resistance Training with Conditioning; Behavioral
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 20 Years to 89 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma
Interventions: Educational Intervention, Electronic Health Record Review, Follow-Up, Internet-Based Intervention, Interview, Survey Administration; Other · Procedure
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Rhytids, Skin Laxity
Interventions: 2,910 nm mid-infrared erbium-doped fluoride fiber glass laser (UltraClear, Acclaro Medical); Device
Lead sponsor: FA Corporation; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Edina, Minnesota

Conditions: Keloid
Interventions: Rapamycin 8% Ointment, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Melanoma, Skin Cancer
Interventions: XL888, Vemurafenib, Cobimetinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: therapeutic estradiol, exemestane, laboratory biomarker analysis, enzyme-linked immunosorbent assay; Biological · Drug · Other
Lead sponsor: University of Arizona; Other
Eligibility: Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Seborrheic Keratosis
Interventions: A-101; Drug
Lead sponsor: Aclaris Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Portland, Oregon • Fort Washington, Pennsylvania • Austin, Texas + 1 more

Conditions: Breast Cancer
Interventions: Intervention; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older · Female only
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Breast Cancer
Interventions: Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine, QS21; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Acne
Interventions: ACYC, ACYC vehicle; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 498 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 24
States / cities: Mobile, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumors, Unresectable Solid Tumor
Interventions: IOV-5001; Biological
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2044
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetic Foot Ulcers
Interventions: Prevention of Diabetic Ulcers; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2001
U.S. locations: 1
States / cities: Seattle, Washington

Search by objective public record fields.

Gemcitabine Plus Ascorbate for Sarcoma in Adults

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

Clinical Study Evaluating an Acetabular Cup System After Total Hip Replacement

Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment for Breast Cancer

Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

Dose Response Study of a Topical Gel for the Treatment of Raynaud's Phenomenon

A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis

Feasibility Study of Barrier Enhancement for Eczema Prevention

EXERT-BC Cardio: Cardio or Conditioning Training With Breast Cancer

A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients

Safety and Efficacy of 2910 nm Fiber Laser Resurfacing and Laser-Coring

RAPA-Keloid Study of Keloid Regression

XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma

Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer

Study of A-101 for the Treatment of Seborrheic Keratosis

Choices for Latinas and Clinical Trials

Vaccine Therapy in Treating Patients at High Risk for Breast Cancer Recurrence

Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne

A Study of IOV-5001 in Adults With Advanced Solid Tumors

Clinical Trials of Footwear in Patients With Diabetes-Study Arm 2,3